This webinar offers investors unique insights into Vera’s (NASDAQ: VERA | $35.02 | $1.9B mkt cap) groundbreaking advancements in treating IgA Nephropathy (IgAN), a chronic kidney disease that causes inflammation and impairs kidney function. This disease often progresses to end-stage kidney disease, requiring dialysis or a transplant. Despite its prevalence, there are limited disease-modifying treatments for IgAN which may represent a $6-10 billion market.

Dr. Fordyce will discuss the significant progress made with Vera’s lead product candidate, atacicept, a first-in-class B cell modulator, as reflected in this year’s 125% stock appreciation. Earlier this year, Vera announced positive 72-week data from the open label extension period of the Phase 2b ORIGIN clinical trial. Their demonstration of stable eGFR well beyond a year in participants receiving atacicept represents an important potential advancement for IgAN patients and has implications for the future treatment paradigm. In addition, Vera is on track to complete enrollment in the pivotal Phase 3 ORIGIN 3 trial in the third quarter of 2024, with primary endpoint data available in the first half of 2025.

By attending this webinar, you will learn about the innovative science behind Vera Therapeutics and understand the significant market potential and upcoming catalysts that make Vera an attractive investment opportunity. Don’t miss this chance to engage with the leader of a pioneering company and discover why Vera Therapeutics should be on your investment radar.

Email eric@lifesciadvisors.com for additional information.